Literature DB >> 1742844

Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor.

Y Kondo1, M Satoh, N Imura, M Akimoto.   

Abstract

The effects of bismuth nitrate pretreatment on the toxicity and antitumor activity of cis-diamminedichloroplatinum (cisplatin, CDDP) were examined in nude mice that had been inoculated with human bladder-tumor tissue. Pretreatment with bismuth nitrate depressed the renal toxicity of CDDP without compromising its activity against a transplantable human bladder tumor. Renal metallothionein (MT) and bismuth (Bi) levels in nude mice were markedly increased by Bi preadministration, but no significant MT induction was observed in inoculated human bladder-tumor tissue in which only a trace amount of Bi was incorporated. Furthermore, it was confirmed that tumor platinum (Pt) concentrations in CDDP-treated mice were not affected by Bi pretreatment. Thus, the administration of Bi compounds prior to chemotherapy with CDDP may provide an effective mode of treatment for advanced bladder tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742844     DOI: 10.1007/bf00686330

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

Review 1.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

2.  Human hepatic metallothioneins.

Authors:  R H Bühler; J H Kägi
Journal:  FEBS Lett       Date:  1974-02-15       Impact factor: 4.124

3.  Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.

Authors:  J J Sternberg; R B Bracken; P B Handel; D E Johnson
Journal:  JAMA       Date:  1977-11-21       Impact factor: 56.272

4.  Binding of bismuth in the kidneys of the rat: the role of metallothionein-like proteins.

Authors:  J A Szymanska; E M Mogilnicka; B W Kaszper
Journal:  Biochem Pharmacol       Date:  1977-02-01       Impact factor: 5.858

5.  Comparison of methods for estimating hepatic metallothionein in rats.

Authors:  F N Kotsonis; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1977-12       Impact factor: 4.219

6.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

7.  Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.

Authors:  G S Baldew; C J van den Hamer; G Los; N P Vermeulen; J J de Goeij; J G McVie
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

8.  cis-Platinum: subcellular distribution and binding to cytosolic ligands.

Authors:  R P Sharma; I R Edwards
Journal:  Biochem Pharmacol       Date:  1983-09-15       Impact factor: 5.858

9.  Clinical pharmacology of high-dose cisplatin.

Authors:  B J Corden; R L Fine; R F Ozols; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum in mice.

Authors:  M Satoh; A Naganuma; N Imura
Journal:  J Pharmacobiodyn       Date:  1989-04
View more
  2 in total

1.  Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Authors:  Per Boye Hansen; Milena Penkowa
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603

2.  HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice.

Authors:  H Toyoda; T Mizushima; M Satoh; N Iizuka; A Nomoto; H Chiba; M Mita; A Naganuma; S Himeno; N Imura
Journal:  Jpn J Cancer Res       Date:  2000-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.